Baricitinib for Refractory Takayasu Arteritis

Inclusion Criteria: * Male or female aged 18-70 years at time of screening. * Diagnosis of Takayasu arteritis (according to the 2022 ACR/EULAR) for ≥3 months before screening. * Active Takayasu arteritis at time of screening (NIH score≥2). * Resistant to traditional therapies and anti-TNF-α therapy for at least 12 months. * Given their written informed consent to participate in the trial and expected to be able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: * TKA-related active major organ involvement requiring immunosuppressive therapy, e.g., pulmonary (e.g., pulmonary artery aneurysm), vascular (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis). * High-dose glucocorticoid (\>1mg/kg/d) usage within 1 month. * Severe comorbidities: including heart failure (≥ grade III NYHA), renal insufficiency (creatinine clearance ≤30 ml/min), hepatic insufficiency (serum ALT or AST \>3 times the ULN, or total bilirubin \>ULN for the central laboratory conducting the test). Other severe, progressive or uncontrolled hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis). * Known allergies, hypersensitivity, or intolerance to Baricitinib or its excipients. * Had a severe infection (including, but not limited to hepatitis, pneumonia, sepsi…